These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 26931357

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.
    Oppici E, Fargue S, Reid ES, Mills PB, Clayton PT, Danpure CJ, Cellini B.
    Hum Mol Genet; 2015 Oct 01; 24(19):5500-11. PubMed ID: 26199318
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correlation between the molecular effects of mutations at the dimer interface of alanine-glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6.
    Dindo M, Oppici E, Dell'Orco D, Montone R, Cellini B.
    J Inherit Metab Dis; 2018 Mar 01; 41(2):263-275. PubMed ID: 29110180
    [Abstract] [Full Text] [Related]

  • 7. The ILE56 mutation on different genetic backgrounds of alanine:glyoxylate aminotransferase: Clinical features and biochemical characterization.
    Dindo M, Mandrile G, Conter C, Montone R, Giachino D, Pelle A, Costantini C, Cellini B.
    Mol Genet Metab; 2020 Mar 01; 131(1-2):171-180. PubMed ID: 32792227
    [Abstract] [Full Text] [Related]

  • 8. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1.
    Danpure CJ.
    J Nephrol; 1998 Mar 01; 11 Suppl 1():8-12. PubMed ID: 9604801
    [Abstract] [Full Text] [Related]

  • 9. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria.
    Belostotsky R, Lyakhovetsky R, Sherman MY, Shkedy F, Tzvi-Behr S, Bar R, Hoppe B, Reusch B, Beck BB, Frishberg Y.
    J Mol Med (Berl); 2018 Jul 01; 96(7):621-630. PubMed ID: 29777253
    [Abstract] [Full Text] [Related]

  • 10. The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I.
    Mesa-Torres N, Fabelo-Rosa I, Riverol D, Yunta C, Albert A, Salido E, Pey AL.
    PLoS One; 2013 Jul 01; 8(8):e71963. PubMed ID: 24205397
    [Abstract] [Full Text] [Related]

  • 11. Molecular aetiology of primary hyperoxaluria type 1.
    Danpure CJ.
    Nephron Exp Nephrol; 2004 Jul 01; 98(2):e39-44. PubMed ID: 15499210
    [Abstract] [Full Text] [Related]

  • 12. Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1.
    Grottelli S, Annunziato G, Pampalone G, Pieroni M, Dindo M, Ferlenghi F, Costantino G, Cellini B.
    J Med Chem; 2022 Jul 28; 65(14):9718-9734. PubMed ID: 35830169
    [Abstract] [Full Text] [Related]

  • 13. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways.
    Danpure CJ.
    Biochim Biophys Acta; 2006 Dec 28; 1763(12):1776-84. PubMed ID: 17027096
    [Abstract] [Full Text] [Related]

  • 14. The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I.
    Oppici E, Montioli R, Dindo M, Maccari L, Porcari V, Lorenzetto A, Chellini S, Voltattorni CB, Cellini B.
    ACS Chem Biol; 2015 Oct 16; 10(10):2227-36. PubMed ID: 26161999
    [Abstract] [Full Text] [Related]

  • 15. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
    Kukreja A, Lasaro M, Cobaugh C, Forbes C, Tang JP, Gao X, Martin-Higueras C, Pey AL, Salido E, Sobolov S, Subramanian RR.
    Nucleic Acid Ther; 2019 Apr 16; 29(2):104-113. PubMed ID: 30676254
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1.
    Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM.
    Proc Natl Acad Sci U S A; 2014 Oct 07; 111(40):14406-11. PubMed ID: 25237136
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Liver peroxisomal alanine:glyoxylate aminotransferase and the effects of mutations associated with Primary Hyperoxaluria Type I: An overview.
    Oppici E, Montioli R, Cellini B.
    Biochim Biophys Acta; 2015 Sep 07; 1854(9):1212-9. PubMed ID: 25620715
    [Abstract] [Full Text] [Related]

  • 19. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria.
    Pey AL, Salido E, Sanchez-Ruiz JM.
    Amino Acids; 2011 Nov 07; 41(5):1233-45. PubMed ID: 21103899
    [Abstract] [Full Text] [Related]

  • 20. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.
    Fargue S, Lewin J, Rumsby G, Danpure CJ.
    J Biol Chem; 2013 Jan 25; 288(4):2475-84. PubMed ID: 23229545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.